Skip to main content

Digital endpoint research collaboration

We are actively seeking research partnerships to expand the evidence base for digital neuroscience assessment. Both the NeuroQuantix spiral analysis platform and FaceWise memory consolidation assessment are available for investigator-initiated studies, grant-funded research, and multi-site validation programs.

Our scoping review of 120 studies in Movement Disorders Clinical Practice identified the standardization gaps that our platforms address. Your research can help close them.

Research Opportunities

Two products, two distinct research programs. Both offer collaborative opportunities for academic investigators and research institutions.

NeuroQuantix Validation Study

Designed. Enrollment Planned

A prospective, multi-site, observational study designed to establish the full psychometric properties of the NeuroQuantix Spiral Analysis Platform as a Clinical Outcome Assessment for movement disorders. The study protocol is finalized and designed for Smart IRB across four academic medical centers.

N=300 across 9 clinical groups
4 academic medical center sites
Longitudinal design with structured follow-up
Central IRB oversight (Smart IRB)
Test-retest reliability, known-groups validity, concurrent validity, sensitivity to change

FaceWise Memory Consolidation Research

Open for Collaboration

FaceWise implements the FNAME paradigm with AI-administered overnight delayed recall. Research opportunities span validation of consolidation-based endpoints across the Alzheimer continuum, sleep architecture studies, and decentralized trial methodology.

Overnight free recall validation across SMC, MCI, and AD populations
Sleep architecture and consolidation deficit correlation studies
Decentralized trial methodology validation
Comparison with standard 30-minute cognitive batteries
Biomarker-consolidation correlation studies (amyloid, tau PET)
Designed. Enrollment Planned

NeuroQuantix Validation Study

A prospective, multi-site, observational study to establish the full psychometric properties of the NeuroQuantix platform as a Clinical Outcome Assessment for movement disorders. We welcome additional academic sites with movement disorder patient populations and established research infrastructure.

N = 300
Target Enrollment
9
Clinical Groups
Longitudinal
Study Design
Smart IRB
IRB Model

Target Academic Sites

Massachusetts General Hospital
Beth Israel Deaconess Medical Center
NYU Langone Health
Northwestern University

Primary Endpoints

Test-retest reliability (ICC)
Known-groups validity (AUC)
Concurrent validity (anchor correlations)
Sensitivity to change (responsiveness)

How we support your research

Platform Access

NeuroQuantix and FaceWise deployed for your study population with configured data exports, assessment protocols, and technical documentation.

Grant Support

Measurement methodology sections for grant applications, power analyses based on published effect sizes, and letters of support for funding agencies.

Study Design Consultation

Protocol design input on endpoint selection, assessment scheduling, sample size calculations, and digital endpoint integration with traditional scales.

Multi-Site Coordination

Standardized training materials, site qualification procedures, and centralized data quality monitoring across your research sites.

Co-Authorship

Collaborative research agreements with co-authorship opportunities. Your data, your questions, our measurement infrastructure.

Data and Analytics

CDISC-compatible data exports, kinematic feature extraction documentation, and statistical analysis support for your research team.

Frequently Asked Questions

How can researchers access NeuroQuantix or FaceWise for their studies?

Investigators running grant-funded or investigator-initiated studies can integrate NeuroQuantix or FaceWise as digital endpoints. We provide technical support, data export configuration, and co-authorship opportunities. Contact us to discuss your study design and how our platforms fit your research objectives.

What is the NeuroQuantix validation study?

A prospective, multi-site, observational study designed across four academic medical centers to establish test-retest reliability, known-groups validity, concurrent validity, and sensitivity to change for the NeuroQuantix platform. N=300 across 9 clinical groups with Smart IRB oversight.

Can researchers use NeuroQuantix data in their publications?

Yes. Collaborative research agreements include co-authorship opportunities and data sharing arrangements. NeuroQuantix provides CDISC-compatible data exports that integrate with standard research data management workflows.

What grant support does Cerebral Innovations provide?

We provide measurement methodology sections for grant applications, technical documentation for IRB submissions, power analyses based on published effect sizes, and letters of support. Published data from our scoping review in Movement Disorders Clinical Practice strengthens the evidence base for grant reviewers.

Ready to collaborate?

Tell us about your research program. Whether you are planning a validation study, an investigator-initiated trial, or a grant application, we would welcome the conversation.

Start the Conversation